Metacrine Revenue and Competitors

Location

$173M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Metacrine's estimated annual revenue is currently $1.4M per year.(i)
  • Metacrine's estimated revenue per employee is $77,500
  • Metacrine's total funding is $173M.

Employee Data

  • Metacrine has 18 Employees.(i)
  • Metacrine grew their employee count by -33% last year.

Metacrine's People

NameTitleEmail/Phone
1
VP Clinical OperationsReveal Email/Phone
2
EVP Human ResourcesReveal Email/Phone
3
Chief Medical OfficerReveal Email/Phone
4
Executive DirectorReveal Email/Phone
5
Director Clinical OperationsReveal Email/Phone
6
Manager, Facilities and PurchasingReveal Email/Phone
7
Research ScientistReveal Email/Phone
8
Accounting ManagerReveal Email/Phone
9
ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Metacrine?

Metacrine is a privately held biotech company ?founded in 2015 on technology licensed from the ?laboratory of Dr. Ronald Evans, a world leader in? nuclear hormone receptors and Howard Hughes?Medical Institute Investigator at the Salk Institute. Metacrine will leverage two mechanistically distinct programs to target diabetes, steatohepatitis and other metabolic and liver disorders.

keywords:N/A

$173M

Total Funding

18

Number of Employees

$1.4M

Revenue (est)

-33%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Metacrine News

2022-04-17 - Metacrine, Inc. (NASDAQ:MTCR) CEO Preston Klassen Sells 44748 ...

Metacrine, Inc. (NASDAQ:MTCR) CEO Preston Klassen Sells 44,748 Shares. Posted by admin on Apr 20th, 2022. Share on Twitter Share on Facebook Share on...

2022-03-30 - Metacrine Reports Fourth-Quarter 2021 Results | News | bakersfield ...

Metacrine, Inc. is a clinical-stage biopharmaceutical company developing differentiated therapies to treat gastrointestinal diseases. Metacrine...

2022-03-30 - Metacrine Reports Fourth-Quarter 2021 Results

Metacrine, Inc. is a clinical-stage biopharmaceutical company developing differentiated therapies to treat gastrointestinal diseases. Metacrine...

2020-09-16 - Metacrine, a Rich Hey­man biotech tar­get­ing NASH and oth­er liv­er dis­eases, rais­es $85M from IPO

A Rich Hey­man-backed start­up fo­cus­ing on NASH treat­ments, as well as oth­er liv­er, GI and meta­bol­ic dis­eases, is set to start trad­ing Wednes­day and join the al­ready-loaded class of 2020 biotech IPOs. Metacrine has raised $85 mil­lion for its pub­lic of­fer­ing af­ter priced shares a ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.5M18-40%N/A
#2
$2.4M18-33%N/A
#3
$1.4M18-18%N/A
#4
$1.4M18-10%$406.5M
#5
$2.2M18N/AN/A